128 related articles for article (PubMed ID: 37625991)
1. Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" [Vaccine 41(1) (2023) 85-91].
Homaira N; Strachan R; Quinn H; Beggs S; Bhuiyan M; Bowen A; Fawcett LK; Gilbert GL; Lambert SB; Macartney K; Marshall HS; Martin AC; McCallum G; McCullagh A; McDonald T; Selvadurai H; McIntyre P; Oftadeh S; Ranganathan S; Saunders T; Suresh S; Wainwright C; Wilson A; Wong M; Jaffe A; Snelling T
Vaccine; 2023 Oct; 41(42):6401-6402. PubMed ID: 37625991
[No Abstract] [Full Text] [Related]
2. Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.
Homaira N; Strachan R; Quinn H; Beggs S; Bhuiyan M; Bowen A; Fawcett LK; Gilbert GL; Lambert SB; Macartney K; Marshall HS; Martin Md AC; McCallum G; McCullagh A; McDonald T; Selvadurai H; McIntyre P; Oftadeh S; Ranganathan PhD S; Saunders T; Suresh S; Wainwright C; Wilson A; Wong M; Jaffe A; Snelling T
Vaccine; 2023 Jan; 41(1):85-91. PubMed ID: 36400662
[TBL] [Abstract][Full Text] [Related]
3. Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia.
Strachan R; Homaira N; Beggs S; Bhuiyan MU; Gilbert GL; Lambert SB; Macartney K; Marshall H; Martin AC; McCallum GB; McCullagh A; McDonald T; McIntyre P; Oftadeh S; Ranganathan S; Suresh S; Wainwright CE; Wilson A; Wong M; Snelling T; Jaffé A
Thorax; 2021 May; 76(5):487-493. PubMed ID: 33504566
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia.
Perdrizet J; Lai YS; Williams S; Struwig VA; Wasserman M
Infect Dis Ther; 2021 Mar; 10(1):507-520. PubMed ID: 33575966
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 13-valent pneumococcal conjugate vaccine against hypoxic pneumonia and hospitalisation in Eastern Highlands Province, Papua New Guinea: An observational cohort study.
Blyth CC; Britton KJ; Nguyen CD; Sapura J; Kave J; Nivio B; Chan J; Satzke C; Ford R; Kirarock W; Lehmann D; Pomat W; Russell FM
Lancet Reg Health West Pac; 2022 May; 22():100432. PubMed ID: 35308576
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal disease in South Australia: vaccine success but no time for complacency.
Johnson DR; D'Onise K; Holland RA; Raupach JC; Koehler AP
Vaccine; 2012 Mar; 30(12):2206-11. PubMed ID: 22273663
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause V; McIntyre P
Vaccine; 2015 Nov; 33(48):6666-74. PubMed ID: 26519550
[TBL] [Abstract][Full Text] [Related]
8. High nasopharyngeal carriage of non-vaccine serotypes in Western Australian aboriginal people following 10 years of pneumococcal conjugate vaccination.
Collins DA; Hoskins A; Bowman J; Jones J; Stemberger NA; Richmond PC; Leach AJ; Lehmann D
PLoS One; 2013; 8(12):e82280. PubMed ID: 24349245
[TBL] [Abstract][Full Text] [Related]
9. Determining the contribution of Streptococcus pneumoniae to community-acquired pneumonia in Australia.
Yin JK; Jayasinghe SH; Charles PG; King C; Chiu CK; Menzies RI; McIntyre PB
Med J Aust; 2017 Nov; 207(9):396-400. PubMed ID: 29092707
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the implementation of the 13-valent pneumococcal vaccine supplementary dose program in Australian primary health care settings.
Ward KF; Trent M; Hull BP; Quinn HE; Dey A; Menzies RI
BMC Health Serv Res; 2015 Mar; 15():109. PubMed ID: 25889782
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.
Lucero MG; Dulalia VE; Nillos LT; Williams G; Parreño RA; Nohynek H; Riley ID; Makela H
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004977. PubMed ID: 19821336
[TBL] [Abstract][Full Text] [Related]
12. Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: Case-control and time-trend studies.
Baqui AH; Koffi AK; McCollum ED; Roy AD; Chowdhury NH; Rafiqullah I; Ahmed ZB; Mahmud A; Begum N; Ahmed S; Khanam R; Harrison M; Simmons N; Hossen S; Islam M; Quaiyum A; Checkley W; Santosham M; Moulton LH; Saha SK;
Vaccine; 2021 Sep; 39(40):5794-5801. PubMed ID: 34465471
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugate vaccine for young children.
Selman S; Hayes D; Perin LA; Hayes WS
Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
[TBL] [Abstract][Full Text] [Related]
14. Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study.
Chan J; Gidding HF; Blyth CC; Fathima P; Jayasinghe S; McIntyre PB; Moore HC; Mulholland K; Nguyen CD; Andrews R; Russell FM
PLoS Med; 2021 Aug; 18(8):e1003733. PubMed ID: 34343186
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
16. Invasive Pneumococcal Disease Surveillance, 1 October to 31 December 2017.
Pennington K;
Commun Dis Intell (2018); 2019 Feb; 43():. PubMed ID: 30739430
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal Conjugate Vaccine impact assessment in Bangladesh.
Baqui AH; McCollum ED; Saha SK; Roy AK; Chowdhury NH; Harrison M; Hanif AAM; Simmons N; Mahmud A; Begum N; Ahmed S; Khan AM; Ahmed ZB; Islam M; Mitra D; Quaiyum A; Chavez MA; Pervaiz F; Miele CH; Schuh HB; Khanam R; Checkley W; Moulton LH; Santosham M
Gates Open Res; 2018 Apr; 2():21. PubMed ID: 29984359
[TBL] [Abstract][Full Text] [Related]
18. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Shrestha S; Gurung M; Amatya P; Bijukchhe S; Bose AS; Carter MJ; Gautam MC; Gurung S; Hinds J; Kandasamy R; Kelly S; Khadka B; Maskey P; Mujadidi YF; O'Reilly PJ; Pokhrel B; Pradhan R; Shah GP; Shrestha S; Wahl B; O'Brien KL; Knoll MD; Murdoch DR; Kelly DF; Thorson S; Voysey M; Pollard AJ;
Lancet Glob Health; 2022 Oct; 10(10):e1494-e1504. PubMed ID: 36113533
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a retrospective, population-based, record-linked cohort study.
Fathima P; Gidding HF; McIntyre PB; Snelling TL; McCallum L; de Klerk N; Blyth CC; Liu B; Moore HC
Lancet Child Adolesc Health; 2019 Oct; 3(10):713-724. PubMed ID: 31439496
[TBL] [Abstract][Full Text] [Related]
20. Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare?
Lowbridge C; McIntyre PB; Gilmour R; Chiu C; Seale H; Ferson MJ; Gilbert GL
Vaccine; 2015 Jun; 33(28):3234-41. PubMed ID: 25952557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
